Ascendiant Capital Markets reiterates a 'Buy' rating, citing significant undervaluation and projecting a potential 1,460% upside for the e-commerce firm.
FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
The fund, BGTF II, is now the world's largest private fund dedicated to clean energy and decarbonization, signaling strong investor confidence.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
The China-based education firm's shares plummeted to an all-time low without any immediate news, deepening concerns over its financial stability and exchange listing.
The healthcare data firm will leverage Palantir's AI platform to enhance its real-world clinical data network, fueling investor optimism.
Mining equities like Argo Blockchain and Hive Digital are posting massive gains, outperforming Bitcoin as investors seek high-beta crypto exposure.